Press release
Atopic Dermatitis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Atopic Dermatitis Overview
Eczema, also called atopic dermatitis, is a common allergic skin disease that usually starts in early childhood. It can be associated with infection (bacteria, fungi, yeast and viruses) of the skin. Atopic dermatitis is common worldwide. People of all ages from newborns to adults 65 years of age and older live with this condition. Half of patients with moderate to severe eczema also suffer from asthma, hay fever (allergic rhinitis), and food allergies.
"Atopic Dermatitis Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atopic Dermatitis Market.
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Atopic Dermatitis Pipeline Report: https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years. Atopic Dermatitis Key players such as - Nektar Therapeutics, Golden Biotechnology Corporation, Ichnos Sciences, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others, are developing therapies for the Atopic Dermatitis treatment
• Atopic Dermatitis Emerging therapies such as - NKTR-358, Antroquinonol, ISB 830, Tradipitant, Roflumilast, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.
• In January 2021, Arcutis Biotherapeutics initiated a Phase III trial titled "A Phase 3, 4-Week, Parallel Group, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis"
Atopic Dermatitis Pipeline Therapeutics Assessment
• Atopic Dermatitis Assessment by Product Type
• Atopic Dermatitis By Stage and Product Type
• Atopic Dermatitis Assessment by Route of Administration
• Atopic Dermatitis By Stage and Route of Administration
• Atopic Dermatitis Assessment by Molecule Type
• Atopic Dermatitis by Stage and Molecule Type
DelveInsight's Atopic Dermatitis Report covers around 100+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:
• NKTR-358: Nektar Therapeutics
• Antroquinonol - Golden Biotechnology Corporation
• ISB 830: Ichnos Sciences
• Tradipitant - Vanda Pharmaceuticals
• Roflumilast: Arcutis Biotherapeutics
Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Assessment- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Atopic Dermatitis Pipeline Analysis:
The Atopic Dermatitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Atopic Dermatitis treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
• Atopic Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Atopic Dermatitis product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies at:
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Atopic Dermatitis Pipeline Market Drivers
• Rising prevalence of Atopic Dermatitis
• Escalating expenditure on health care
Atopic Dermatitis Pipeline Market Barriers
• Over-the-counter medications
• Outdated Atopic Dermatitis treatment recommendations
• Poor prognosis and treatment adherence
Scope of Atopic Dermatitis Pipeline Drug Insight
• Coverage: Global
• Key Atopic Dermatitis Companies: Nektar Therapeutics, Golden Biotechnology Corporation, Ichnos Sciences, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others
• Key Atopic Dermatitis Therapies: NKTR-358, Antroquinonol, ISB 830, Tradipitant, Roflumilast, and others
• Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
• Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers
Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Atopic Dermatitis Report Introduction
2 Atopic Dermatitis Executive Summary
3 Atopic Dermatitis Overview
4 Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment
5 Atopic Dermatitis Pipeline Therapeutics
6 Atopic Dermatitis Late Stage Products (Phase II/III)
7 Atopic Dermatitis Mid Stage Products (Phase II)
8 Atopic Dermatitis Early Stage Products (Phase I)
9 Atopic Dermatitis Preclinical Stage Products
10 Atopic Dermatitis Therapeutics Assessment
11 Atopic Dermatitis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Atopic Dermatitis Key Companies
14 Atopic Dermatitis Key Products
15 Atopic Dermatitis Unmet Needs
16 Atopic Dermatitis Market Drivers and Barriers
17 Atopic Dermatitis Future Perspectives and Conclusion
18 Atopic Dermatitis Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Atopic Dermatitis Market https://www.delveinsight.com/report-store/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atopic Dermatitis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Atopic Dermatitis Epidemiology https://www.delveinsight.com/report-store/atopic-dermatitis-ad-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atopic Dermatitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2828208 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Atopic
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…
